` ASND (Ascendis Pharma A/S) vs S&P 500 Comparison - Alpha Spread

ASND
vs
S&P 500

Over the past 12 months, ASND has outperformed S&P 500, delivering a return of 30% compared to the S&P 500's 12% growth.

Stocks Performance
ASND vs S&P 500

Loading

Performance Gap
ASND vs S&P 500

Loading
ASND
S&P 500
Difference

Performance By Year
ASND vs S&P 500

Loading
ASND
S&P 500
Add Stock

Competitors Performance
Ascendis Pharma A/S vs Peers

S&P 500
ASND
ABBV
AMGN
GILD
VRTX
Add Stock

Ascendis Pharma A/S
Glance View

Market Cap
9.6B USD
Industry
Biotechnology

Ascendis Pharma A/S has established itself as a dynamic force within the biotechnology sphere, driven by a patented technology platform designed to address unmet medical needs. Founded in 2006 and headquartered in Denmark, the company has honed its focus on developing therapies to improve patients' lives by addressing significant health conditions, primarily in the fields of endocrinology and oncology. At the heart of its strategy is the TransCon technology, which revolves around prodrug methodologies that release active drug molecules at controlled rates, enhancing efficacy and reducing side effects. This platform allows Ascendis to develop extended-release versions of existing drugs, ensuring a more sustained therapeutic effect. Financially, Ascendis generates revenue by forging strategic partnerships and licensing agreements, enabling it to share in the commercialization success of its innovative pipeline products. By collaborating with larger pharmaceutical firms, Ascendis scales its impact, leveraging shared resources and expertise to bring its specialized treatments to market. Moreover, as its pipeline matures, it seeks to capitalize on successful clinical trials by moving products into commercial phases, which can result in additional income streams from direct product sales. The journey of Ascendis Pharma is emblematic of its commitment to innovation, sustainability, and delivering tangible healthcare advances through its robust technology-driven approach.

ASND Intrinsic Value
146.67 USD
Overvaluation 7%
Intrinsic Value
Price
Back to Top